Clinical Trial Update: Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a combination of bortezomib, arsenic trioxide, and melphalan in patients undergoing autologous stem cell transplant for multiple myelom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Alkeran (melphalan)
• Trisenox (arsenic trioxide)
• Velcade (bortezomib)

Snippet

Sponsor: University of Miami | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 1 | Status: WITHDRAWN